SC-IFX Concentrations and Therapeutic Outcomes in IBD

Higher serum infliximab concentrations following subcutaneous dosing were associated with deep remission among patients with inflammatory bowel disease (IBD), a recent study published in Journal of Crohn’s and Colitis found.

The cross-sectional study included 71 adults with IBD treated with subcutaneous infliximab [SC-IFX] concentrations at a maintenance dose of 120 mg/2 weeks. The primary therapeutic outcomes included sustained clinical remission; composite clinical and biomarker remission (clinical remission and C-reactive protein <5 mg/L); biochemical remission (fecal calprotectin <250 µg/g); and deep remission (clinical, biological, and biochemical remission).

At the time of drug concentration measurement, 77% of the patients had sustained clinical remission (n = 55); 62% had composite clinical and biomarker remission (n = 44); 56% had biochemical remission (n = 40); and 43% achieved deep remission (n = 31). Among these patients who achieved higher therapeutic outcomes, the mean SC-IFX concentrations were significantly higher.

Upon multivariate analyses, the investigators confirmed that SC-IFX concentration was the only factor independently associated with sustained clinical remission, clinical and biomarker remission, biochemical remission, and deep remission.

“Serum SC-IFX concentrations >20 µg/mL were significantly associated with deep remission,” the team concluded.

Reference:
Xavier R, Stéphane N, Konstantinos P et al. Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease. Journ of Crohn's and Colitis. 2023. DOI: https://doi.org/10.1093/ecco-jcc/jjad188